Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.

Dihydrofolate reductase (DHFR) inhibitors such as trimethoprim (TMP) have long played a significant role in the treatment of bacterial infections. Not surprisingly, after decades of use there is now bacterial resistance to TMP and therefore a need to develop novel antibacterial agents with expanded spectrum including these resistant strains. In this study, we investigated the optimization of 2,4-diamnoquinazolines for antibacterial potency and selectivity. Using structure-based drug design, several 7-aryl-2,4-diaminoquinazolines were discovered that have excellent sub-100 picomolar potency against bacterial DHFR. These compounds have good antibacterial activity especially on gram-positive pathogens including TMP-resistant strains.

[1]  L. Sorbera,et al.  Iclaprim. Antibacterial dihydrofolate reductase inhibitor , 2004 .

[2]  P. Caspers,et al.  Antistaphylococcal Activity of Dihydrophthalazine Antifolates, a Family of Novel Antibacterial Drugs , 2009, Antimicrobial Agents and Chemotherapy.

[3]  J. Hynes,et al.  Direct synthesis of 2,4-diaminoquinazolines from 2-fluorobenzonitriles , 1988 .

[4]  G. Eliopoulos,et al.  Resistance to trimethoprim-sulfamethoxazole. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  S. Queener,et al.  Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. , 2005, Journal of medicinal chemistry.

[6]  N. Priestley,et al.  Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase. , 2008, Journal of medicinal chemistry.

[7]  R. Then,et al.  DNA and RNA synthesis: antifolates. , 2005, Chemical reviews.

[8]  S. Queener,et al.  N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase. , 2008, Journal of medicinal chemistry.

[9]  K. Bowden,et al.  Antifolate and antibacterial activities of 5-substituted 2,4-diaminoquinazolines. , 1990, Journal of medicinal chemistry.

[10]  K. Berlin,et al.  Inhibition of Antibiotic-Resistant Staphylococcus aureus by the Broad-Spectrum Dihydrofolate Reductase Inhibitor RAB1 , 2010, Antimicrobial Agents and Chemotherapy.

[11]  R. Then.  History and future of antimicrobial diaminopyrimidines. , 1993, Journal of chemotherapy.

[12]  Peter E Wright,et al.  Structure, dynamics, and catalytic function of dihydrofolate reductase. , 2004, Annual review of biophysics and biomolecular structure.

[13]  J. Freisheim,et al.  Inhibition of human dihydrofolate reductase by 2,4-diaminoquinazolines bearing simple substituents on the aromatic ring , 1991 .